Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 03, 2026 07:00 ET | Source: Medicenna Therapeutics Corp.

Medicenna’s MDNA11 Potential in Earlier Line Melanoma Setting Highlighted in Presentation of the NEO-CYT trial at ASCO 2026

NEO-CYT positions MDNA11 in a frontline neoadjuvant melanoma setting, where immunotherapy before surgery may help generate deeper and more durable anti-tumor immune responses Up to 80 patients with...
May 28, 2026 09:10 ET | Source: Medicenna Therapeutics Corp.

Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs

NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO, May 28, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”)...
May 22, 2026 07:00 ET | Source: Medicenna Therapeutics Corp.

Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet

NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO and HOUSTON, May 22, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the...
May 19, 2026 07:00 ET | Source: Medicenna Therapeutics Corp.

Medicenna Announces the Finalization of the Terms of its Public Offering of Securities

Base shelf prospectus is accessible, and prospectus supplement will be accessible within two business days on SEDAR+1 TORONTO and HOUSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics...
May 13, 2026 16:01 ET | Source: Medicenna Therapeutics Corp.

Medicenna Announces the Launch of a Marketed Public Offering of Securities

NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO and HOUSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the...
May 12, 2026 07:00 ET | Source: Medicenna Therapeutics Corp.

Medicenna and Fondazione Melanoma Onlus Announce First Patient Dosed in the NEO-CYT Study of MDNA11 in Neoadjuvant Melanoma

NEO-CYT marks the first evaluation of MDNA11 in earlier-stage cancers, as a potentially curative treatment; extends development beyond the heavily pretreated metastatic setting of the ongoing Phase...
April 30, 2026 07:30 ET | Source: Medicenna Therapeutics Corp.

Medicenna and Fondazione Melanoma Onlus Announce Presentation on NEOCYT Trial at ASCO 2026

TORONTO and HOUSTON, April 30, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company developing...
April 21, 2026 07:30 ET | Source: Medicenna Therapeutics Corp.

Medicenna Presents Positive Data Demonstrating Superior Safety and Efficacy Potential of its First-in-Class anti-PD-1 x IL-2 Bifunctional Superkine MDNA113 at AACR 2026

New in vivo data demonstrate exceptional selectivity, localization and potency of MDNA113 in the tumor and tumor microenvironment while enhancing the systemic tolerability profile Head-to-head...
April 14, 2026 07:30 ET | Source: Medicenna Therapeutics Corp.

Medicenna to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference

TORONTO and HOUSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company...
April 09, 2026 07:00 ET | Source: Medicenna Therapeutics Corp.

Medicenna Therapeutics Appoints Dr. Nageatte Ibrahim as Chief Medical Officer

TORONTO and HOUSTON, April 09, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company...